<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127044</url>
  </required_header>
  <id_info>
    <org_study_id>263337</org_study_id>
    <nct_id>NCT05127044</nct_id>
  </id_info>
  <brief_title>Characterization of Pre-Term Neonatal Skin</brief_title>
  <official_title>Characterization of Pre-Term Neonatal Skin by Diffuse Reflectance Spectroscopy Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The skin of pre-term neonates is not fully developed and often leads to trans-epidermal water&#xD;
      loss, trouble regulating temperature, and increased risk of skin wounds. Current treatment&#xD;
      decisions are based on subjective, qualitative assessments of the skin. The purpose of this&#xD;
      pilot study is to evaluate the utility of non-invasive optical spectroscopy methods to&#xD;
      collect key biological information from neonatal skin, including skin maturity, blood&#xD;
      oxygenation, and bilirubin content. Parents of pre-term neonatal subjects (n=44) will be&#xD;
      recruited for consent to participate, and spectral measurements will be made with a diffuse&#xD;
      reflectance spectrometer(DRS) device previously approved by the University of Arkansas for&#xD;
      Medical Sciences Institutional Review Board. The spectral data will be analyzed to extract&#xD;
      parameters related to tissue light scattering, oxy-and deoxy-hemoglobin, melanin, and&#xD;
      bilirubin. The system will be validated by comparing extracted spectra with expected&#xD;
      literature values and directly correlating the measured bilirubin levels with readouts from&#xD;
      the current University of Arkansas for Medical Sciences practice standard: Philip's BiliChek.&#xD;
      The long-term goal is to develop and use non-invasive optical readouts to predict and monitor&#xD;
      skin dysfunction in the Neonatal Intensive Care Unit (NICU).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a cross-sectional, pilot study to characterize the response of neonatal premature&#xD;
      skin to DRS when excited with a white light source, and provide a baseline of how the&#xD;
      collected spectra change with the maturation of the epidermal layer in the weeks to term&#xD;
      gestation after birth. DRS spectra and BiliChek measurements will be performed on the study&#xD;
      population admitted to the Neonatal Intensive Care Unit. The pilot data will be used to&#xD;
      evaluate whether Diffuse Reflectance Spectroscopy spectra can be used to extract optical&#xD;
      information on skin maturity as well as hemoglobin, melanin, and bilirubin concentrations.&#xD;
      The investigators will extract spectra for each chromophore and the relative concentration&#xD;
      from the Diffuse Reflectance Spectroscopy measurements. Extracted Diffuse Reflectance&#xD;
      Spectroscopy spectra will be compared to published absorbance spectra for each chromophore.&#xD;
      The criteria for success will be a high, positive correlation (r ≥ 0.85) between the&#xD;
      extracted Diffuse Reflectance Spectroscopy bilirubin concentration and BiliChek-derived&#xD;
      concentration.&#xD;
&#xD;
      The following coded data will also be collected to investigate correlations with the Diffuse&#xD;
      Reflectance Spectroscopy spectra: blood oxygen saturation, weight, ethnicity, corrected age,&#xD;
      gestational age, sex, most recent complete blood count (if available, or partial count if&#xD;
      not), most recent chemistry levels, lipids, liver profile, and blood gas (all if available).&#xD;
      BiliChek measurements of bilirubin content will be compared to the extracted bilirubin&#xD;
      contribution measured from the Diffuse Reflectance Spectroscopy spectra using linear&#xD;
      regression and assessed using Pearson's correlation coefficient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of diffuse reflectance spectroscopy spectra with expected variable outcome values</measure>
    <time_frame>approximately one month per subject</time_frame>
    <description>Number of participants with premature skin will be assessed for skin integrity and study variable readings using DRS system by comparing extracted spectra with expected values by gestational age</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-invasive diffuse reflectance spectroscopy vs BiliChek</measure>
    <time_frame>approximately one month per subject</time_frame>
    <description>Number of participants with premature skin will be assessed for study variable transcutaneous bilirubin readings using DRS system by comparing extracted spectra with expected values by gestational age and correlating the measured bilirubin levels using Diffuse Reflectance Spectroscopy (DRS) with readouts from the current UAMS practice standard: Philip's BiliChek</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard use of Non-Invasive Optical Spectroscopy on Preterm Infants</measure>
    <time_frame>approximately one month per subject</time_frame>
    <description>The long-term goal is to develop and use non-invasive optical readouts to predict and monitor skin dysfunction in the Neonatal ICU</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Skin Disorder</condition>
  <arm_group>
    <arm_group_label>Qualified Preterm Infants</arm_group_label>
    <description>Preterm infants will receive non-invasive optical spectroscopy and transcutaneous bilirubin testing for baseline comparison</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diffuse Reflectance Spectroscopy</intervention_name>
    <description>DRS will be used as a non-invasive optical spectroscopy method to collect key biological information from neonatal skin including skin maturity, blood oxygenation, and bilirubin content.</description>
    <arm_group_label>Qualified Preterm Infants</arm_group_label>
    <other_name>DRS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>BiliChek</intervention_name>
    <description>BiliChek will be used as a control for determining bilirubin content.</description>
    <arm_group_label>Qualified Preterm Infants</arm_group_label>
    <other_name>Transcutaneous Bilirubin Reading</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study population to include premature infants less than 37 weeks gestation meeting born at&#xD;
        University of Arkansas for Medical Sciences admitted to the NICU.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants less than or equal to 37 weeks gestation at birth&#xD;
&#xD;
          -  Current care provided by the UAMS NICU&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infants entering palliative care&#xD;
&#xD;
          -  Infants with known liver disease&#xD;
&#xD;
          -  Infants on isolation precautions&#xD;
&#xD;
          -  Infants at end of life&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Sartini, DNP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Sartini, DNP</last_name>
    <phone>501526-1580</phone>
    <email>rpsartini@uams.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kyle Quinn, PhD</last_name>
    <phone>4795735384</phone>
    <email>kpquinn@uark.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rebecca Sartini, DNP</last_name>
      <phone>501-526-1580</phone>
      <email>rpsartini@uams.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Smith, MSN</last_name>
      <phone>5015261500</phone>
      <phone_ext>Sartini</phone_ext>
      <email>rpsartini@uams.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rebecca Sartini, DNP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jacques, S.L., D.G. Oelberg, and I. Saidi, Method and apparatus for optical measurement of bilirubin in tissue. 1994, Board of Regents, The University of Texas System: United States.</citation>
  </reference>
  <results_reference>
    <citation>Afsar FS. Physiological skin conditions of preterm and term neonates. Clin Exp Dermatol. 2010 Jun;35(4):346-50. doi: 10.1111/j.1365-2230.2009.03562.x. Epub 2009 Sep 15. Review.</citation>
    <PMID>19758381</PMID>
  </results_reference>
  <results_reference>
    <citation>Zonios G, Bykowski J, Kollias N. Skin melanin, hemoglobin, and light scattering properties can be quantitatively assessed in vivo using diffuse reflectance spectroscopy. J Invest Dermatol. 2001 Dec;117(6):1452-7.</citation>
    <PMID>11886508</PMID>
  </results_reference>
  <results_reference>
    <citation>Subhash N, Mallia JR, Thomas SS, Mathews A, Sebastian P, Madhavan J. Oral cancer detection using diffuse reflectance spectral ratio R540/R575 of oxygenated hemoglobin bands. J Biomed Opt. 2006 Jan-Feb;11(1):014018.</citation>
    <PMID>16526895</PMID>
  </results_reference>
  <results_reference>
    <citation>Qualter YM, Allen NM, Corcoran JD, O'Donovan DJ. Transcutaneous bilirubin--comparing the accuracy of BiliChek® and JM 103® in a regional postnatal unit. J Matern Fetal Neonatal Med. 2011 Feb;24(2):267-70. doi: 10.3109/14767058.2010.484471. Epub 2010 May 19.</citation>
    <PMID>20482289</PMID>
  </results_reference>
  <results_reference>
    <citation>Rajaram N, Nguyen TH, Tunnell JW. Lookup table-based inverse model for determining optical properties of turbid media. J Biomed Opt. 2008 Sep-Oct;13(5):050501. doi: 10.1117/1.2981797.</citation>
    <PMID>19021373</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bilirubin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

